Black Rock Inc. Actinium Pharmaceuticals, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,875,425 shares of ATNM stock, worth $2.44 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,875,425
Previous 1,708,988
9.74%
Holding current value
$2.44 Million
Previous $13.4 Million
3.71%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ATNM
# of Institutions
64Shares Held
6.8MCall Options Held
42.3KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA1.38MShares$1.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny625KShares$812,1060.0% of portfolio
-
Acadian Asset Management LLC Boston, MA490KShares$636,4500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA328KShares$426,9440.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny289KShares$375,2190.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $32.7M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...